These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35963791)

  • 1. [What a cardiologist needs to know about managing a patient with multiple myeloma].
    Gilles F
    Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):309-316. PubMed ID: 35963791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cardiovascular risk in patients with multiple myeloma.
    Plummer C; Driessen C; Szabo Z; Mateos MV
    Blood Cancer J; 2019 Feb; 9(3):26. PubMed ID: 30808934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
    Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M;
    Haematologica; 2018 Sep; 103(9):1422-1432. PubMed ID: 30049825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances.
    Camilli M; La Vecchia G; Lillo R; Iannaccone G; Lamendola P; Montone RA; Hohaus S; Aspromonte N; Massetti M; Lanza GA; Crea F; Graziani F; Lombardo A
    Expert Rev Hematol; 2021 Dec; 14(12):1115-1128. PubMed ID: 34739762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular complications of multiple myeloma in the elderly.
    Mathur P; Thanendrarajan S; Paydak H; Vallurupalli S; Jambhekar K; Bhatti S; Schinke CD; Davies FE; Mehta JL
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):933-943. PubMed ID: 29164945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma.
    Bertolotti P; Pierre A; Rome S; Faiman B
    Semin Oncol Nurs; 2017 Aug; 33(3):332-347. PubMed ID: 28729122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
    Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of myeloma: an update.
    Meenaghan T; Hayat A; Walpole G; Dowling M
    Br J Nurs; 2023 Sep; 32(17):S4-S12. PubMed ID: 37737854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis.
    Nuvolone M; Basset M; Palladini G
    Expert Opin Drug Saf; 2021 Apr; 20(4):411-426. PubMed ID: 33583294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombosis in multiple myeloma (MM).
    Cesarman-Maus G; Braggio E; Fonseca R
    Hematology; 2012 Apr; 17 Suppl 1(0 1):S177-80. PubMed ID: 22507814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
    Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
    Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of novel agents in multiple myeloma patients with hepatic impairment.
    Stansfield LC; Gonsalves WI; Buadi FK
    Future Oncol; 2015; 11(3):501-10. PubMed ID: 25675129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of heart failure symptoms, disease severity, treatment decision-making, and side effects by patients and cardiologists: a multinational survey in a cardiology setting.
    Wirta SB; Balas B; Proenca CC; Bailey H; Phillips Z; Jackson J; Cotton S
    Ther Clin Risk Manag; 2018; 14():2265-2272. PubMed ID: 30532549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
.
    King T; Faiman B
    Clin J Oncol Nurs; 2017 Apr; 21(2):240-249. PubMed ID: 28315528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.